Search
Dogwood Therapeutics Inc
DWTXAdd to Watchlist
1.490USD
-0.010-0.67%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
49.77MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-0.67%
5 Days
-9.70%
1 Month
-11.31%
6 Months
-64.86%
Year to Date
-64.18%
1 Year
-68.96%
Key Figures
1.540Open
1.610High
107.76KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.32%Turnover Ratio
1.500Prev. Close
1.450Low
140.38KTurnover
LossP/E Static
0.62P/B
0.00%Div Yield TTM
-37.14%ROA
9.50052wk High
1.63Volume Ratio
-13.38MNet Profit
33.40MShares
-7.1350EPS TTM
1.71Beta
-109.66%ROE
1.28052wk Low
10.67%Amplitude
--Gross Margin
49.77MMarket Cap
-2.00Reward/Risk
5.36%Risk Rate
TradingKey Stock Score of Dogwood Therapeutics Inc
Currency: USD Updated: 2026-07-02Key Insights
Dogwood Therapeutics Inc's fundamentals are relatively weak, and its growth potential is high.Its valuation is considered fairly valued, ranking 211 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 14.00.In the medium term, the stock price is expected to trend down.The company has shown weak stock market performance over the past month, in line with its weak fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Dogwood Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Dogwood Therapeutics Inc Highlights
StrengthsRisks
Dogwood Therapeutics, Inc. is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and fatigue-related disorders. The Company’s research pipeline includes two separate mechanistic platforms with a non-opioid analgesic program and an antiviral program. The proprietary, non-opioid, Nav 1.7 analgesic program is centered on its lead development candidate, Halneuron, which is a specific voltage-gated sodium channel modulator, a mechanism known to be effective for reducing pain transmission. In clinical studies, Halneuron treatment has demonstrated pain reduction in pain related to general cancer and in pain related to chronic chemotherapy-induced neuropathic pain (CINP). The Company’s antiviral program includes IMC-1 and IMC-2, which are fixed-dose combinations of nucleoside analog, anti-herpes antivirals and the anti-inflammatory agent celecoxib for the treatment of fibromyalgia (FM) and Long-COVID (LC).
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Overvalued
The company’s latest PE is -0.21, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 3.70M shares, increasing 49.44% quarter-over-quarter.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
14.000
Target Price
+833.33%
Upside Space
Dogwood Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Dogwood Therapeutics Inc Info
Dogwood Therapeutics, Inc. is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and fatigue-related disorders. The Company’s research pipeline includes two separate mechanistic platforms with a non-opioid analgesic program and an antiviral program. The proprietary, non-opioid, Nav 1.7 analgesic program is centered on its lead development candidate, Halneuron, which is a specific voltage-gated sodium channel modulator, a mechanism known to be effective for reducing pain transmission. In clinical studies, Halneuron treatment has demonstrated pain reduction in pain related to general cancer and in pain related to chronic chemotherapy-induced neuropathic pain (CINP). The Company’s antiviral program includes IMC-1 and IMC-2, which are fixed-dose combinations of nucleoside analog, anti-herpes antivirals and the anti-inflammatory agent celecoxib for the treatment of fibromyalgia (FM) and Long-COVID (LC).
Ticker SymbolDWTX
CompanyDogwood Therapeutics Inc
CEODuncan (Gregory Scott)
Websitehttps://dwtx.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Dogwood Therapeutics Inc (DWTX)?
The current price of Dogwood Therapeutics Inc (DWTX) is 1.49.
What is the symbol of Dogwood Therapeutics Inc?
The ticker symbol of Dogwood Therapeutics Inc is DWTX.
What is the 52-week high of Dogwood Therapeutics Inc?
The 52-week high of Dogwood Therapeutics Inc is 9.50.
What is the 52-week low of Dogwood Therapeutics Inc?
The 52-week low of Dogwood Therapeutics Inc is 1.28.
What is the market capitalization of Dogwood Therapeutics Inc?
The market capitalization of Dogwood Therapeutics Inc is 49.77M.
Is Dogwood Therapeutics Inc (DWTX) currently rated as Buy, Hold, or Sell?
According to analysts, Dogwood Therapeutics Inc (DWTX) has an overall rating of Buy, with a price target of 14.00.
What is the Earnings Per Share (EPS TTM) of Dogwood Therapeutics Inc (DWTX)?
The Earnings Per Share (EPS TTM) of Dogwood Therapeutics Inc (DWTX) is -7.13.